Abbott Laboratories said Tuesday that it received marketing approval for a version of its i-STAT 1 blood testing system that can transmit results wirelessly.
Abbott said the Food and Drug Administration cleared the device. It said the wireless system can save time by transmitting results while caregivers remain at a patient’s bed side.
Shares of Abbott rose 12 cents, to $48.20, in afternoon trading.
